JP2009507792A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507792A5
JP2009507792A5 JP2008529160A JP2008529160A JP2009507792A5 JP 2009507792 A5 JP2009507792 A5 JP 2009507792A5 JP 2008529160 A JP2008529160 A JP 2008529160A JP 2008529160 A JP2008529160 A JP 2008529160A JP 2009507792 A5 JP2009507792 A5 JP 2009507792A5
Authority
JP
Japan
Prior art keywords
alkyl
aliphatic
optionally substituted
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008529160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507792A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/033510 external-priority patent/WO2007027594A1/en
Publication of JP2009507792A publication Critical patent/JP2009507792A/ja
Publication of JP2009507792A5 publication Critical patent/JP2009507792A5/ja
Pending legal-status Critical Current

Links

JP2008529160A 2005-08-29 2006-08-29 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン Pending JP2009507792A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71264205P 2005-08-29 2005-08-29
PCT/US2006/033510 WO2007027594A1 (en) 2005-08-29 2006-08-29 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2009507792A JP2009507792A (ja) 2009-02-26
JP2009507792A5 true JP2009507792A5 (enExample) 2009-10-08

Family

ID=37440897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008529160A Pending JP2009507792A (ja) 2005-08-29 2006-08-29 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン

Country Status (7)

Country Link
US (1) US7691885B2 (enExample)
EP (1) EP1919891B1 (enExample)
JP (1) JP2009507792A (enExample)
AT (1) ATE548363T1 (enExample)
AU (1) AU2006285038A1 (enExample)
CA (1) CA2620269A1 (enExample)
WO (1) WO2007027594A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5112317B2 (ja) 2005-08-29 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン
WO2007027729A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2420846T3 (es) * 2008-02-05 2013-08-27 F. Hoffmann-La Roche Ag Nuevas piridinonas y piridazinonas
PE20100851A1 (es) * 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
PL2300459T3 (pl) 2008-07-02 2013-10-31 Hoffmann La Roche Nowe fenylopirazynony jako inhibitory kinazy
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PL2989106T3 (pl) 2013-04-25 2017-08-31 Beigene, Ltd. Połączone związki heterocykliczne jako inhibitory kinazy białkowej
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CA2996177A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
IL293319B1 (en) 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
CN109982687A (zh) 2016-09-19 2019-07-05 梅制药公司 联合疗法
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
CN119899148B (zh) * 2025-01-10 2025-12-19 江西中医药大学 水仙根中的两个生物碱类化合物及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238576A (en) 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
KR100196559B1 (ko) 1990-06-19 1999-06-15 기따사또 이찌로 안지오텐신ii 길항작용을 함유하는 피리딘 유도체
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
DE4221583A1 (de) 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
DE4314964A1 (de) 1993-05-06 1994-11-10 Bayer Ag Pyridinylmethyl-substiutierte Pyridine und Pyridone
DE4314963A1 (de) 1993-05-06 1994-11-10 Bayer Ag Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
CZ20003978A3 (cs) 1998-04-27 2001-09-12 Centre National De La Recherche Scientifique Deriváty 3-(amino- nebo aminoalkyl) pyridinonu a jejich použití
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
EP1343763A1 (en) 2000-11-20 2003-09-17 Bristol-Myers Squibb Company Pyrodone derivatives as ap2 inhibitors
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
CA2442428A1 (en) 2001-03-28 2002-10-10 Mark D. Wittman Novel tyrosine kinase inhibitors
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法
AU2003274025A1 (en) 2002-10-17 2004-05-04 Syngenta Participations Ag Pyridine derivatives useful as herbicides
WO2004035563A1 (en) 2002-10-17 2004-04-29 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
CA2506741A1 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
AU2003300297A1 (en) 2002-12-23 2004-07-22 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST Beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2005007159A1 (en) 2003-07-14 2005-01-27 The General Hospital Corporation Methods for treating vascular diseases
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
MX2007001399A (es) 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
MX2007007330A (es) * 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
WO2007027729A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
JP5112317B2 (ja) 2005-08-29 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのtecファミリーの阻害剤として有用な3,5−二置換ピリド−2−オン

Similar Documents

Publication Publication Date Title
JP2009506123A5 (enExample)
RU2007126832A (ru) Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически опосредованных заболеваний
JP7536064B2 (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
JP2003507456A5 (enExample)
TWI706958B (zh) 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
ES2715507T3 (es) Derivados de quinazolina usados para tratar el VIH
ES2617763T3 (es) Sal de besilato de un inhibidor de BTK
CN106518924B (zh) 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶
JP2009528991A5 (enExample)
JP6772360B2 (ja) イソクエン酸デヒドロゲナーゼ阻害剤としての化合物、及びその応用
JP5827327B2 (ja) リン酸輸送を阻害する化合物及び方法
IL277146B1 (en) Amino acid compounds and methods of use
JP2020528889A5 (enExample)
RU2019131017A (ru) Соединения гетероарила в качестве ингибиторов btk и их применение
JP2005503394A5 (enExample)
JP2015509098A5 (enExample)
JP2017160233A5 (enExample)
JP2014015465A5 (enExample)
HRP20161010T1 (hr) C5ar antagonisti
CN102177152A (zh) 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
CA2551178A1 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
JP2019533714A5 (enExample)
JP2013536864A5 (enExample)
JP2009507790A5 (enExample)
JP2020527593A5 (enExample)